Pfizer Inc. (NYSE:PFE) Shares Acquired by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 118.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 294,764 shares of the biopharmaceutical company's stock after purchasing an additional 159,984 shares during the quarter. Parsons Capital Management Inc. RI's holdings in Pfizer were worth $7,820,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $26,000. Gladius Capital Management LP lifted its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP purchased a new stake in shares of Pfizer during the second quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management grew its position in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 771 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Up 2.9 %

Shares of PFE stock traded up $0.77 during mid-day trading on Monday, hitting $26.86. 50,613,696 shares of the stock traded hands, compared to its average volume of 35,663,965. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $152.19 billion, a P/E ratio of 36.29, a P/E/G ratio of 0.64 and a beta of 0.64. The stock's fifty day moving average is $26.11 and its two-hundred day moving average is $27.94. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) earnings per share. Equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is 232.43%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 price target on the stock. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.